Oskam J, Danesh-Meyer H
Graefes Arch Clin Exp Ophthalmol. 2024; 262(7):2269-2281.
PMID: 38345654
PMC: 11222285.
DOI: 10.1007/s00417-023-06350-4.
Wang X, Yin D, Tang Y, Xiao F, Wang S
Front Pharmacol. 2023; 14:1209933.
PMID: 37465525
PMC: 10351039.
DOI: 10.3389/fphar.2023.1209933.
Zou X, Zhou P, Lv W, Liu C, Liu J
Front Pharmacol. 2023; 14:1126235.
PMID: 36814495
PMC: 9939648.
DOI: 10.3389/fphar.2023.1126235.
Tseng Y, Chen C, Hong R, Kung W, Huang A
Brain Sci. 2023; 13(1).
PMID: 36672016
PMC: 9856907.
DOI: 10.3390/brainsci13010033.
Lv Y, Zhang Y, Zhang J, Liang N, Liu F, Liu R
Medicine (Baltimore). 2019; 98(46):e17787.
PMID: 31725620
PMC: 6867717.
DOI: 10.1097/MD.0000000000017787.
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.
Chae Y, Chiec L, Adney S, Waitzman J, Costa R, Carneiro B
Oncotarget. 2018; 9(46):28281-28289.
PMID: 29963277
PMC: 6021337.
DOI: 10.18632/oncotarget.25606.
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H
Intern Med. 2017; 57(7):1015-1019.
PMID: 29225265
PMC: 5919864.
DOI: 10.2169/internalmedicine.9593-17.
Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases.
Furubayashi N, Negishi T, Iwai H, Nagase K, Nakamura M
Mol Clin Oncol. 2017; 7(2):281-284.
PMID: 28781802
PMC: 5532681.
DOI: 10.3892/mco.2017.1291.
Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.
Quirino M, Rossi S, Schinzari G, Basso M, Strippoli A, Cassano A
Medicine (Baltimore). 2017; 96(16):e6522.
PMID: 28422839
PMC: 5406055.
DOI: 10.1097/MD.0000000000006522.
Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?.
Shah R
Drug Saf. 2017; 40(5):373-386.
PMID: 28181126
DOI: 10.1007/s40264-017-0508-3.
Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report.
Dos Reis Simoes da Silva F, Burgos Pego P, Henriques Vendrell M, de Azevedo Batalha Ferreira Dos Santos Farias M, Ribeiro Timoteo A, Martins da Costa M
Neuroophthalmology. 2016; 35(1):32-37.
PMID: 27956931
PMC: 5145282.
DOI: 10.3109/01658107.2010.539763.
Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.
Singer S, Grommes C, Reiner A, Rosenblum M, DeAngelis L
Oncologist. 2015; 20(7):806-11.
PMID: 26032137
PMC: 4492224.
DOI: 10.1634/theoncologist.2014-0149.
Reversible posterior encephalopathy syndrome secondary to sunitinib.
Costa R, Costa R, Costa R, Junior G, Cartaxo H, de Barros A
Case Rep Oncol Med. 2014; 2014:952624.
PMID: 24900933
PMC: 4037124.
DOI: 10.1155/2014/952624.
Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.
Kim C, Price-Hiller J, Chu Q, Tankel K, Hennig R, Sawyer M
Invest New Drugs. 2014; 32(5):1036-45.
PMID: 24853074
DOI: 10.1007/s10637-014-0113-6.
Posterior reversible leukoencephalopathy syndrome associated with pazopanib.
Foerster R, Welzel T, Debus J, Gruellich C, Jaeger D, Potthoff K
Case Rep Oncol. 2013; 6(1):204-8.
PMID: 23626562
PMC: 3636956.
DOI: 10.1159/000350742.
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S
Target Oncol. 2011; 6(4):253-8.
PMID: 22090260
DOI: 10.1007/s11523-011-0201-x.
